Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)"

Circulation. 2014 Oct 21;130(17):e152. doi: 10.1161/CIRCULATIONAHA.114.010927.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cardiovascular Diseases*
  • Female
  • Fluorobenzenes / administration & dosage*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
  • Lipoprotein(a) / blood*
  • Male
  • Pyrimidines / administration & dosage*
  • Sulfonamides / administration & dosage*

Substances

  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoprotein(a)
  • Pyrimidines
  • Sulfonamides